ClinicalTrials.gg
RecruitingNCT05879757Updated Feb 18, 2026

Real-world Usage of HyQvia in Multiple Myeloma Adults With Secondary Immunodeficiency

An observational study in Multiple Myeloma and Secondary Immunodeficiency (SID), sponsored by Takeda. Recruiting at 27 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-18.

Sponsored by Takeda · Observational

How we know

From the registry’s dates

  • Started Oct 2023; still recruiting 3 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
75
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 54 studies in Multiple Myeloma by Takeda — 2 open to participants now, 4 under way, 1 of them phase 3. Multiple Myeloma · Takeda.

Planned enrollment
11th of 13
75 · median 295
Started
2023
with 1 other
Observational
13 of 54
1 open now
Registered
52nd of 54
by date

Among the 54 studies in Multiple Myeloma by Takeda, this one is the 11th largest by planned enrollment of the 13 observational ones that give a count, is one of 2 that started in 2023, is one of 13 observational ones, and was the 52nd registered.

Multiple Myeloma

3,764 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

2 of the 54 studies in Multiple Myeloma by Takeda are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 583 Multiple Myeloma studies recruiting now, 428 (73%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies in Multiple Myeloma by Takeda, or all of them as a file.
02

Study summary

In this study, multiple myeloma participants with secondary immunodeficiency (SID) will be treated with HyQvia according to their clinic's standard practice. The study's main aim is to look into infusion parameters of HyQvia administration.

Read the detailed description

This is a prospective, observational study of adults having multiple myeloma (MM) with SID treated with HyQvia as part of routine clinical care. This study will characterize the real-world infusion parameters of HyQvia administration.

The study will enroll approximately 100 participants.

Study data will be requested through participants' routine clinic visits and patient-reported outcome (PRO)s are voluntary.

This multi-center trial will be conducted in selected European and South American countries. The overall time of this study is 38 months. Participants will make multiple visits to the clinic within 12 months after enrolment for follow-up assessments.

03

Conditions studied

  • Multiple Myeloma
  • Secondary Immunodeficiency (SID)

Browse trials for

Keywords

  • Drug Therapy
  • Supportive Therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population will include adult participants who suffer from MM, have a diagnosis of SID defined according to the European HyQvia label.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants who meet all of the following criteria assessed at the time of enrollment are eligible for this study:

  1. Ability and willingness to provide . For adult participants unable to provide informed consent, informed consent provided by the legally authorized representative (LAR).
  2. Has a diagnosis of MM requiring systemic anti-myeloma therapy as per International Myeloma Working Group (IMWG) criteria.
  3. Initiated HyQvia treatment as part of routine clinical care no more than 30 days before study enrollment or received no more than 2 doses of HyQvia treatment, whichever occurs first. Participants are also eligible if they newly start HyQvia within 30 days after the enrollment visit.

    Note: Participants who do not start HyQvia treatment within 30 days of enrollment will be considered as screen failures (and replaced).

  4. Age >=18 years old at the time of MM diagnosis.
  5. Available medical history records starting from the diagnosis of MM requiring systemic anti-myeloma therapy as IMWG criteria.
  6. >6 months at the time of enrollment, per physician assessment.
  7. (ECOG) performance status score of \<=2.
  8. Participants/LAR willing and able to comply with the requirements of the protocol.

Exclusion criteria

Exclusion Criteria:

Participants who meet any of the following criteria assessed at the time of enrollment are not eligible for this study:

  1. Known to any of the components of HyQvia.
  2. Primary immunodeficiency (PID) or diagnosed with /acquired immunodeficiency syndrome (HIV/AIDS) and/or active and/or active infection.
  3. Prior use of Ig treatment or prophylaxis within 3 months from the date of enrollment.
  4. Serious infection(s) requiring intravenous (IV) treatment at the time of enrollment into the study; except for participants on short-term oral antibiotic therapy.
  5. Has participated in an interventional clinical study involving a medicinal product or device within 30 days prior to enrollment or is scheduled to participate in an interventional clinical study involving a medical product or device during this study.

    Note: Participants on chimeric antigen receptor-T (CAR-T) cell therapies and/or bispecific antibodies may participate.

  6. Planned stem cell transplant during the treatment period or had a prior stem cell transplant: transplant at any time, autologous transplant within 3 months of enrollment.
  7. History of (other than MM) within 3 years before the date of enrollment (exceptions are squamous and basal cell carcinomas of the skin, carcinoma in situ of the cervix or breast, localized prostate cancer or other non-invasive lesion that in the opinion of the investigator, is considered cured with minimal risk of recurrence within 3 years).
  8. Participant has had major surgery within 2 weeks before enrollment, or has not fully recovered from an earlier surgery, or has surgery planned during the time the participant is expected to participate in the study.

Note: Participants with planned surgical procedures to be conducted under local anesthesia may participate. Kyphoplasty or vertebroplasty are not considered major surgery.

Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
75 participants (estimated)
Patient registry
No

Groups and cohorts

  • MM Participants With SID

    Participants with MM diagnosed with SID will be treated with HyQvia as part of routine clinical care and will be followed prospectively from the date of starting HyQvia treatment through 12 months of follow-up.

    Other: No Intervention

Interventions

  • OtherNo Intervention

    As this is an observational study, no intervention will be administered in this study.

06

What researchers measure

Primary outcomes

  1. Dose of HyQvia per Kilogram of Body Weight

    Dose of HyQvia will be calculated as grams per kilogram (g/kg) body weight per 4 weeks.

    Time frame: Up to 12 months

  2. Absolute Dose of HyQvia per Infusion

    Absolute dose of HyQvia will be calculated as dose per infusion in milligrams (mg).

    Time frame: Up to 12 months

  3. Treatment Interval

    Treatment interval and ramp up dosing intervals will be reported as Weekly, every 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks and other administration according to the schedule defined by physician.

    Time frame: Up to 12 months

  4. Infusion Volume per Site

    Time frame: Up to 12 months

  5. Total Infusion Volume

    Time frame: Up to 12 months

  6. Infusion Rate

    Infusion rate will be reported in milliliters per hour (mL/h).

    Time frame: Up to 12 months

  7. Duration of Infusion

    The duration between start and end of infusion will be reported.

    Time frame: Up to 12 months

  8. Location of Infusion Sites

    Location of infusion sites will include right upper abdomen, left upper abdomen, right lower abdomen, left lower abdomen, right or left thigh, right or left arm, and other (specified).

    Time frame: Up to 12 months

  9. Number of Infusion Sites

    Time frame: Up to 12 months

  10. Number of Participants Characterized by Site of Care

    Site of care will be categorized as home, hospital, doctor's office, other (specified).

    Time frame: Up to 12 months

  11. Length and Diameter of Infusion Needles

    Time frame: Up to 12 months

  12. Number of Participants per Type of Pump

    Type of pump will include peristaltic infusion pump and syringe driver pump.

    Time frame: Up to 12 months

  13. Number of Participants With Availability of Caregiver Support

    Availability of caregiver support will be collected as yes, no, and unknown. If yes, caregiver relationship will be specified.

    Time frame: Up to 12 months

  14. Number of Training Visits

    Time frame: Up to 12 months

  15. Number of Participants With Infusions That are Discontinued, Slowed, or Interrupted

    Time frame: Up to 12 months

  16. Number of Participants With Reasons of infusions Discontinued, Slowed, or Interrupted

    Time frame: Up to 12 months

  17. Number of Participants With Reasons for Discontinued, or Interrupted HyQvia Treatment or Switches to Other Treatment

    Reasons for discontinued, or interrupted HyQvia treatment will include local adverse events (AE)/discomfort, systemic AE, administration complexity, insurance/reimbursement-related, low immunoglobulin (Ig) trough level, lack of effectiveness, inability to tolerate large volumes, death and other (specified). If switch, type of treatment after switch (example, antibiotic treatment, intravenous immunoglobulin \[IVIg\], subcutaneous immunoglobulin \[SCIg\], unknown) or switches to other treatment will be included.

    Time frame: Up to 12 months

Secondary outcomes

  1. Time of Multiple Myeloma (MM) Diagnosis

    Time frame: At the time of baseline

  2. Number of Participants Characterized by Clinical Characteristics

    Clinical characteristics of participants will include type of MM, and MM treatment/procedures, comorbidities, concomitant medications, laboratory tests and imaging.

    Time frame: Up to 12 months

  3. Number of Participants Characterized With Type of Hemato-oncological Treatment

    Type of hemato-oncological treatment will list type, switches, interruptions and discontinuation with reasons of hemato-oncological treatment or procedure.

    Time frame: Baseline up to 12 months

  4. Duration of Hemato-oncological Treatment

    Time frame: Baseline up to 12 months

  5. Number of Participants With Multiple Myeloma (MM) Disease Status and Outcome at 12 Months

    MM disease status and outcome will include response and criteria used to assess response (if known).

    Time frame: Month 12

  6. Overall Survival (OS)

    OS will be summarized as the frequency and percentage of participants surviving to each follow-up visit. Additionally, time-to death, defined as the time from HyQvia initiation to death occurring before the end of the study period, will be assessed.

    Time frame: Up to 12 months

  7. Number of Participants With Healthcare Resource Utilization (HCRU)

    Number of participants with HCRU including annualized rates and emergency room visits, urgent care visits, outpatient visits, telemedicine visits, and other physician visits, with stratification of hospitalizations and visits due to infection, visit type and provider type.

    Time frame: Up to 12 months

  8. Duration of Hospitalizations

    Time frame: Up to 12 months

  9. Number of Participants With Related and Not Related Serious Adverse Events (SAEs)

    An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An SAE is defined as an untoward medical occurrence that at any dose is fatal, life-threatening, requires inpatient hospitalisation or results in prolongation of an existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a medically important event. AEs will be reported as local or systemic AEs.

    Time frame: Up to 12 months

  10. Number of Participants With Non-serious Adverse Events (AEs) Causally or Temporally Related to HyQvia Treatment

    An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. AEs will be reported as local or systemic AEs.

    Time frame: Up to 12 months

  11. Number of Participants With Premedication use for HyQvia Infusions, any Technical Problems With the Infusion, and the Planned Versus Actual Dosing

    Premedication use for HyQvia infusions will include start date, stop date and medication name. Technical problems with infusion will include problems with the handling of the pump, problems with the preparation of the infusion, problems with the infusion itself, infusion site leakage, and other (specified).

    Time frame: Up to 12 months

07

Study locations

14 of 27 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/ For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2023 (actual). Primary completion is estimated for Feb 2027, 39 months after the start.

Of 66 industry-sponsored observational studies under Multiple Myeloma, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 70. This study's planned 39 months is below that.

Counting every sponsor, half of 239 studies reached it within 57 months; a quarter within 30 and three quarters within 126.

How these figures are worked out, and which studies are left out of them.

Registered
May 19, 2023
First posted
May 30, 2023
StartActual
Oct 17, 2023
Primary completionEst.
Feb 16, 2027
CompletionEst.
Feb 16, 2027
Last update
Feb 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05879757
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
May 30, 2023
Start date
Oct 17, 2023
Primary completion
Feb 16, 2027 (estimated)
Completion
Feb 16, 2027 (estimated)
Last update
Feb 18, 2026

Study contacts

Takeda Contact
Contact
medinfoUS@takeda.com
+1-877-825-3327
Study Director
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion